Literature DB >> 32827064

Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation.

Hiroki Hosoi1, Shogo Murata2, Toshiki Mushino2, Akinori Nishikawa2, Takashi Sonoki2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32827064     DOI： 10.1007/s00277-020-04226-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  8 in total

1.  Eosinophilia indicates the evolution to acute graft-versus-host disease.

Authors:  Nadezda Basara; Michael G Kiehl; Axel A Fauser
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

2.  The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.

Authors:  Thomas Goldner; Guy Hewlett; Nicole Ettischer; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

3.  The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.

Authors:  Martin Schmidt-Hieber; Gloria Tridello; Per Ljungman; Malgorzata Mikulska; Nina Knelange; Didier Blaise; Gerard Socié; Liisa Volin; Nicole Blijlevens; Nathalie Fegueux; Ibrahim Yakoub-Agha; Edouard Forcade; Johan Maertens; Patrice Chevallier; Jakob Passweg; Jan Cornelissen; Nigel Russell; Charles Craddock; Jean Henri Bourhis; Tony Marchand; Péter Reményi; Jean Yves Cahn; Mauricette Michallet; Silvia Montoto; Nicolaus Kröger; Bertram Glaß; Jan Styczynski
Journal:  Ann Hematol       Date:  2019-04-16       Impact factor: 3.673

4.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Authors:  Francisco M Marty; Per Ljungman; Roy F Chemaly; Johan Maertens; Sanjeet S Dadwal; Rafael F Duarte; Shariq Haider; Andrew J Ullmann; Yuta Katayama; Janice Brown; Kathleen M Mullane; Michael Boeckh; Emily A Blumberg; Hermann Einsele; David R Snydman; Yoshinobu Kanda; Mark J DiNubile; Valerie L Teal; Hong Wan; Yoshihiko Murata; Nicholas A Kartsonis; Randi Y Leavitt; Cyrus Badshah
Journal:  N Engl J Med       Date:  2017-12-06       Impact factor: 91.245

5.  Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation.

Authors:  Yoshinobu Aisa; Takehiko Mori; Tomonori Nakazato; Takayuki Shimizu; Rie Yamazaki; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Transpl Int       Date:  2007-06-18       Impact factor: 3.782

6.  Eosinophils from hematopoietic stem cell recipients suppress allogeneic T cell proliferation.

Authors:  Jennie Andersson; Julia Cromvik; Madeleine Ingelsten; Christine Lingblom; Kerstin Andersson; Jan-Erik Johansson; Christine Wennerås
Journal:  Biol Blood Marrow Transplant       Date:  2014-08-28       Impact factor: 5.742

7.  Hypereosinophilia as a presenting sign of acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  D McNeel; M T Rubio; G Damaj; J F Emile; C Belanger; B Varet; N Brousse; O Hermine; A Buzyn
Journal:  Transplantation       Date:  2002-12-27       Impact factor: 4.939

8.  CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT.

Authors:  Martin Schmidt-Hieber; Myriam Labopin; Dietrich Beelen; Liisa Volin; Gerhard Ehninger; Jürgen Finke; Gerard Socié; Rainer Schwerdtfeger; Nicolaus Kröger; Arnold Ganser; Dietger Niederwieser; Emmanuelle Polge; Igor W Blau; Mohamad Mohty
Journal:  Blood       Date:  2013-09-13       Impact factor: 22.113
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.